Amgen, Inc. (NASDAQ:AMGN) declared a quarterly dividend on Friday, December 7th, RTT News reports. Investors of record on Friday, February 15th will be given a dividend of 1.45 per share by the medical research company on Friday, March 8th. This represents a $5.80 annualized dividend and a yield of 3.03%. This is a boost from Amgen’s previous quarterly dividend of $1.32.

Amgen has increased its dividend by an average of 23.5% annually over the last three years and has increased its dividend every year for the last 7 years. Amgen has a dividend payout ratio of 37.8% meaning its dividend is sufficiently covered by earnings. Analysts expect Amgen to earn $14.37 per share next year, which means the company should continue to be able to cover its $5.28 annual dividend with an expected future payout ratio of 36.7%.

NASDAQ AMGN opened at $191.44 on Friday. Amgen has a 1-year low of $163.31 and a 1-year high of $210.19. The company has a market capitalization of $126.81 billion, a P/E ratio of 15.22, a PEG ratio of 2.07 and a beta of 1.41. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The firm had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. During the same period last year, the business posted $3.27 EPS. Amgen’s quarterly revenue was up 2.3% on a year-over-year basis. On average, equities research analysts expect that Amgen will post 14.24 EPS for the current fiscal year.

In other news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.19% of the stock is owned by insiders.

AMGN has been the subject of several recent research reports. Cann reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Monday, October 1st. Royal Bank of Canada reissued a “neutral” rating and set a $193.00 price target on shares of Amgen in a research report on Monday, September 10th. Goldman Sachs Group reissued a “buy” rating and set a $229.00 price target on shares of Amgen in a research report on Friday, October 12th. Oppenheimer reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Finally, Jefferies Financial Group set a $220.00 price target on Amgen and gave the stock a “buy” rating in a research report on Monday, October 8th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Amgen has a consensus rating of “Hold” and a consensus target price of $205.68.

WARNING: “Amgen, Inc. (AMGN) Plans Quarterly Dividend of $1.45” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Article: Balanced Fund

Dividend History for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.